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Abstract. Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It 
prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid 
leukemia (CML).  Imatinib directly inhibits the constitutive tyrosine kinase activity. Imatinib binds 
to BCR-ABL kinase domain by preventing the transfer of a phosphate group to tyrosine on the 
protein substrate and the subsequent activation of phosphorylated protein. As the result, the 
transmission of proliferative signals to the nucleus is blocked and leukemic cell apoptosis is 
induced. The FDA has approved imatinib as first-line treatment for newly diagnosed CML in 
December 2002 following an International Randomized Study (IRIS), initiated in June 2000, 
comparing imatinib at a single daily dose 400 mg to IFN alpha plus cytarabine in newly diagnosed 
patients with CML in CP . Results from this study show the outstanding effectiveness of  imatinib 
and its superiority with respect to the rates of complete hematological response (CHR), major and 
complete cytogenetic response (MCyR, CCyR). Patients randomized to imatinib arm at 8 – year 
data cut off continue to have a durable hematologic and cytogenetic responses, low progression 
rates to AP or BC, and remarkable survival outcomes. An overall survival (OS) rate is 85% for 
patients receiving imatinib (93% when only CML-related deaths and those prior to stem cell 
transplantation are considered). The results have been confirmed  in the last years by several 
groups. According these cumulative results the rates of CCyR achieved after one year of therapy 
with imatinib at standard dose ranged from 49% to 77%, and the proportion of patients who 
achieved major molecular response (MMR) after one year ranged between 18% and 58%. 
Discontinuation of imatinib has been also tried in patients in MMR,  a molecular relapse occurs in 
about one third of patients , generally within 6 months from imatinib cessation. 
 
Introduction. Imatinib was the first signal transduction 
inhibitor (STI), used in a clinical setting. It prevents a 
BCR-ABL protein from exerting its role in the 
oncogenic pathway in chronic myeloid leukemia  
 
 
(CML).  Imatinib directly inhibits the constitutive 
tyrosine kinase activity, which results in the 
modification of the function of various genes involved 
in the control of the cell cycle, cell adhesion, 
cytoskeleton organization and finally in the apoptotic 
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death of Ph(+) cells.1 
Imatinib binds to BCR-ABL kinase domain, which 
is in an inactive conformation in a pocket reserved for 
the ATP binding site, thus preventing the transfer of a 
phosphate group to tyrosine on the protein substrate 
and the subsequent activation of phosphorylated 
protein. As the result, the transmission of proliferative 
signals to the nucleus is blocked and leukemic cell 
apoptosis is induced.2 Preclinial in vitro studies showed 
that imatinib is a tyrosine kinase inhibitor (TKI) of 
ABL kinase and its active derivatives: viral Abelson 
nonreceptor protein tyrosine kinase (v-ABL), BCR-
ABL,3,4  TEL-ABL,5 platelet-derived growth factor 
receptor (PDGFR) and Steel factor receptor (c-KIT) 
kinases.6  Imatinib exhibits high level of selectivity. Its 
activity against the above protein kinases is similar 
with IC50 values in the range of 0.025 M for protein 
autophosphorylation and is at least 100-fold lower than 
for a large number of other tyrosine and 
serine/threonine kinases.6  
 
Pharmacokinetics of Imatinib. Pharmacokinetics of 
imatinib is characterized by rapid and complete oral 
bioavailability (98%) and a proportional dose-exposure 
relationship.18,19 There is no significant interaction of 
imatinib with food intake. Its terminal half-life is 
approximately 18 hours, allowing for once-daily 
dosing.18,19  The median peak plasma concentrations at 
steady state of imatinib administered orally once a day 
at a dose of 400 mg and median trough levels are 5.4 
M, and 1.43 M respectively.7 Imatinib is metabolized 
by the cytochrome P450 system. CYP3A4 is the major 
isoenzyme responsible for imatinib metabolism, 
although CYP1A2, CYP2D6, CYP2C9, and CYP2C19 
also contribute to a minor extent.18,19 The activity of 
CYP enzyme exhibits intrinsic variability, which could 
be the cause of high interpatient unevenness in imatinib 
exposure.18,19 Drugs that are inhibitors or inductors of 
the CYP3A4 isoenzyme have been shown to alter 
imatinib pharmacokinetic activity.20 
 
Efficacy of Imatinib. Phase I trials: The first phase I 
trial was initiated in June 1998 and enrolled patients 
suffering from CML in chronic phase (CP) who were 
resistant to or intolerant of interferon alpha (IFN 
alpha). Almost all patients (98%) treated with at least 
300 mg imatinib per day achieved complete 
hematological response (CHR).  Major and complete 
cytogenetic response (MCyR, CCyR) were obtained by 
31% and 13% of patients respectively. Of note, the 
responses were durable, only 2 relapses (out of 53 
patients) were noted after a median follow-up of 265 
days.8 Based on these results, the  protocol was 
expanded and included 58 patients in blast crisis (BC) 
or with Ph-positive acute lymphoblastic leukemia 
(Ph+ALL). Hematological responses to minimal dose 
of imatinib in this cohort (300 mg daily)  were obtained 
in 55% and 70% of  patients with myeloid,  and 
lymphoid blast crisis respectively, including four CHR 
in each group. Twelve percent of patients achieved 
MCyR and 8% CCyR. Patients treated in BC unlike 
patients treated in the CP relapsed frequently after 
initiating imatinib therapy. Approximately 50% of 
responders with myeloid phenotype and all but one 
responder with lymphoid phenotype relapsed between 
42 and 193 days of imatinib treatment (Druker et al., 
2001b). Patients in accelerated phase (AP) had not 
been studied in the phase I protocols.  
Phase II trials: Three international multicenter phase II 
trials were initiated in 1999. The study population 
included patients with CML in myeloid BC, relapsed 
Ph+ALL, CML in AP, and patients who were resistant 
to IFN alpha. The results achieved in patients suffering 
from BC with myeloid phenotype largely confirmed 
the results obtained in the phase I study.9 In contrast to 
patients with myeloid type of disease, none of patients 
treated for lymphoid blast crisis and for relapsed 
Ph+ALL had durable response to imatinib.10 The 
results of  patients treated for AP fall between those 
observed in myeloid BC and CP with the 1-year 
survival achieved in 74% patients. A retrospective 
comparison between two dose cohorts (400 mg and 
600 mg daily) showed a significantly longer time to 
progression and overall survival for the 600 mg 
cohort.11 Based on these studies the recommended 
daily dose for patients in advanced phases of CML was 
set at 600 mg daily,9,11 and the recommendation of 
increasing the imatinib dose to 600 and 800 mg daily 
was rapidly extended also to patients in CP with 
unsatisfactory response to 400 mg daily, or response 
loss. The patients suffering from CML in CP 
hematologically or cytogenetically resistant or 
refractory, or intolerant of IFN alpha were the largest 
group studied within phase II trials. Ninety five percent 
of all patients achieved CHR; CCyR and MCyR were 
seen in 41% and 60% of patients respectively, and the  
progression-free survival rate at 18 months was 89%.6  
Phase III trials: An International Randomized Study of 
Interferon and STI571 (IRIS) comparing imatinib at a 
single daily dose 400 mg to IFN alpha plus cytarabine 
in newly diagnosed patients with CML in CP was 
initiated in June 2000. Results from this study show the 
outstanding effectiveness of  imatinib and its 
superiority with respect to the rates of CHR, MCyR 
and CCyR. At 18 months, the rate of CCyR in patients 
treated with imatinib was 76% versus 15%  for patients 
treated with IFN alpha plus cytarabine (P < .001). 
Importantly, the rate of progression to AP or BC at 18 
months was significantly reduced in patients 
randomized to imatinib arm.12 Based on these results, 
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the FDA has approved imatinib as first-line treatment 
for newly diagnosed CML in December 2002. At 8 
years of follow-up, 45% of patients had discontinued 
treatment due to adverse events (AEs)/safety (6%), 
unsatisfactory therapeutic outcome (16%), stem cell 
transplantation (SCT) (3%), death (3%) or other 
reasons (17% for withdrawal or lack of renewal of 
consent and miscellaneous). Patients randomized to 
imatinib arm at 8 – year data cut off continue to have a 
durable hematologic and cytogenetic responses, low 
progression rates to AP or BC, and remarkable survival 
outcomes.12-15 An overall survival (OS) rate is 85% for  
patients receiving imatinib (93% when only CML-
related deaths and those prior to stem cell  
 
transplantation are considered), with the annual rates of 
progression to AP or BC in year 4 to 8 after imatinib 
therapy onset are: 0.9%, 0.5%, 0%, 0%, and 0.4%, 
respectively. Progression to AP or BC was noted only 
in 3% of patients who achieved CCyR, and in none of 
patients who achieved major molecular response 
(MMR, < 0.1% BCR-ABL/control gene ratio on 
international scale) at 12 months of therapy.16 The 
patients treated with imatinib who had at 18 months a ≥ 
3 log reduction in the level of BCR-ABL transcripts 
compared with a standardized baseline had a  minimal 
risk of disease progression over the subsequent 12 
months.17  
 
Table. Efficacy of imatinib in front line treatment in major clinical trials 
      
Trial Studied population Imatinib dosage 
Complete 
cytogenetic 
response  
(CCyR) 
rate [%] 
Major 
molecular 
response 
(MMR) 
rate [%] 
Estimated 
progression-free survival 
(PFS) / ,  overall survival 
(OS) 
Phase I trials 
[Druker et al. 
2001a] 
CML patients in chronic phase (CP) 
resistant to or intolerant of IFN alpha 
≥300 
mg/d 13% NR NR 
[Druker et al. 
2001b] 
 
CML patients in blastic phase – myeloid 
 
CML patients in blastic phase – lymphoid 
 
300-
1000 
mg/d 
14% 
 
14% 
NR 
 
NR 
PFS: 84 days / OS: NR 
PFS: 58 days / OS: NR 
Phase II trials 
[Sawyers et al. 
2002] 
 
CML patients in blastic phase – myeloid 
 
400-600 
mg/d 7% NR 
Median response time 10 
months / median survival 
time 6,9 months 
[Ottmann et al. 
2002] 
CML patients in blastic phase – lymphoid 
 
400-600 
mg/d 17% NR 2,2 / 4,9 months 
[Deininger et al. 
2003] 
CML patients in CP resistant or 
refractory, or intolerant of IFN alpha 
400 
mg/d 41% NR 
18 month PFS 89% / 9,2 
months 
Phase III trials 
IRIS study 
[Deininger et al. 
2009] 
CML patients in CP de novo 400 mg/d 
At 8 years: 
83% 
At 8 years: 
86% 
At 8 year: PFS:92% / OS: 
89%; 93% if only CML – 
related deaths considered 
PETHEMA 
[Cervantes et al. 
2010] 
CML patients in CP de novo 400 mg/d 
At 3 years 
(ITT) 
78,8% 
At 3 years 
(ITT) 63% 
At 5 years PFS: 94,3%/ OS: 
97,5% 
SPIRIT 
[Preudhomme et al. 
2010] 
CML patients in CP de novo 
400 
mg/d 
 
 
At 12 
months 
58% 
At 12/24 
months: 
38%/43% 
At 2 years PFS: 97,5% 
GIMEMA 
[Gugliotta et al. 
2011] 
CML patients in CP de novo 
400 
mg/d 
 
 
At 52 
months 
87%-88% 
At 52 
months 
85% 
At 6 years PFS:75/90% / 
OS: 78/92% 
(<65/ ≥65 year-old 
pts.resp.) 
CAMELIA 
[Faber et al. 2013] CML patients in CP de novo 
400 
mg/d 83% NR 
At 5 years PFS:96%/OS: 
90% 
German Study 
Group IV 
[Hehlmann et al. 
2011] 
CML patients in CP de novo 400 mg/d 
At 3 years 
85,2% 
At 3 years 
79% 
At 3 years PFS:94-99% / 
OS:93-99% (for <1% and ≥ 
1% of BCR-ABL resp.) 
DASISION [Saglio 
et al. 2010] CML patients in CP de novo 
400 
mg/d 
At 18 
months 
70% 
At any time 
41% PFS: 93,7% / OS: 97,9% 
ENESTnd 
[Kantarjian et al. 
2010] 
CML patients in CP de novo 400 mg/d 
At 12 
months 
65% 
At any time 
44% PFS 95,2% / OS: 96,4% 
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Combinations of IM and high IM dose 
[Kantarjian et al. 
2004] CML patients in CP de novo 
800 
mg/d 90% 
63% (BCR-
ABL/ABL 
ratio 
<0,05%) 
At 15 months PFS:98% / 
OS: 98,3%% 
European 
LeukemiaNet study 
[Baccarani et al. 
2009] 
CML patients in CP de novo 
400 
mg/d 
 
 
 
800 
mg/d 
At 12 
months 
58% 
 
At 12 
months 
64% 
 
 
At 12 
months 
33,3% 
 
At 12 
months 
39,8% 
At 3 years PFS: 86%/ OS: 
84% 
 
 
 
At 3 years PFS: 88%/ OS: 
91% 
 
[Andreas et al. 
2008] 
 
 
 
[Andreas et al. 
2008] 
 
CML patients in CP de novo 
 
 
 
 
CML patients in CP de novo 
400 
mg/d 
 
 
 
800 
mg/d 
At 6 
months 
20% 
 
44% 
(differences 
not 
significant 
at 12 
months) 
At 6 
months 
7% 
 
20% 
(differences 
not 
significant 
at 12 
months) 
 
NR 
 
 
 
 
NR 
TOPS study 
[Cortes et al. 2008] CML patients in CP de novo 
400 
mg/d 
 
 
 
800 
mg/d 
At 12 
months 
66% 
 
66% 
 
At 12 
months 
40,1% 
 
46,4% 
AT 18 months PFS: 95% / 
OS: 98,7% 
 
 
PFS: 97% / OS: 98,2% 
German Study 
Group IV 
[Hehlmann et al. 
2011] 
CML patients in CP de novo 
800 
mg/d 
 
 
 
 
400 
mg/d + 
IFN 
alpha 
At 3 years 
85,2% 
 
 
 
78,5% 
At 3 years 
79% 
 
 
 
63% 
At 3 years PFS:94%/99% / 
OS: 93/99% (for <1% and ≥ 
1% of BCR-ABL resp.) 
At 2 years PFS: 80,3%/ at 5 
years OS: 91% 
SPIRIT 
[Preudhomme et al. 
2010] 
CML patients in CP de novo 
600 
mg/d 
 
 
 
400 
mg/d + 
IFN 
alpha 
At 12 
months 
65% 
 
66% 
At 12/24 
months 
49%/53% 
 
57%/64% 
At 2 years PFS: 96,9% / OS 
NR 
 
 
At 2 years PFS: 96,8% / OS 
NR 
 
Nordic trial 
[Simonsson et al. 
2011] 
CML patients in CP de novo 
400 
mg/d 
 
 
 
400 
mg/d 
+PegIFN 
At 52 
weeks 
83,9% 
 
91,1% 
At 12 
months 
54% 
 
82% 
NR 
 
 
NR 
MDACC study 
[Cortes et al. 2011] CML patients in CP de novo 
800 
mg/d 
 
 
800 
mg/d 
+PegIFN 
At 12 
months 
87% 
 
90% 
At 12 
months 
77% 
 
77% 
NR 
 
 
 
NR 
NR – not reported 
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The achievement of an MMR continued to be 
associated with an improved outcome at 5-year, with 
estimated rates without progression to AP/BC of 100%, 
98%, and 87% for patients achieving CCyR and MMR, 
CCyR without MMR, and no CCyR, respectively.13 
The best observed MMR rate with the 8-year follow-up 
of IRIS trial is 86%. The results of imatinib first line 
based on analysis of data derived from clinical trials 
and registries have been reported in the last three years 
by several groups (PETHEMA, SPIRIT, GIMEMA, 
CAMELIA, German Study Group IV, and others.).21-30 
The rates of CCyR achieved after one year of therapy 
with imatinib at standard dose ranged from 49% to 
77%, and the proportion of patients who achieved 
MMR after one year ranged between 18% and 58%.  
The Efficacy of Imatinib at Higher Dose; 
Combinations with other Agents. Preclinical data and 
some observations from single – arm studies suggested 
that higher dosages of imatinib could be more effective 
than standard 400 mg once daily dose, and may 
provide a better disease control. The amplification of 
the BCR-ABL gene or overexpression of bcr-abl 
protein kinase are two known mechanisms of relative 
resistance to imatinib34-36  which could be overcome by 
dosages of 600 mg or 800 mg daily. However the 
initial reports that high dose imatinib treatment results 
in better, and achieved more rapidly responses than 
during standard dose imatinib remain controversial. 
Kantarjian et al. reports that compared with standard-
dose imatinib, the dose of 800 mg daily was associated 
with achievement of significantly better rates of CCyR, 
major (defined as BCR-ABL/ABL ratio ≤ 0.05%), and 
complete (BCR-ABL/ABL negative)  molecular 
responses. Transformation-free survival in this cohort 
of patients was significantly better with high-dose 
imatinib. Similar frequency of common adverse events 
with that seen with standard-dose imatinib were 
reported. The most common causes for dose reduction 
were myelosuppression.37 The German Study Group IV 
randomized trial compared imatinib 800 mg daily with 
standard dose imatinib +/- IFN in newly diagnosed 
CML patients in CP with regard to molecular response 
at 12 months and survival. Of 218 patients receiving 
imatinib 800 mg and evaluable for dosage at 12 months 
45.9% received more than 700 mg/day. The cumulative 
incidences of CCyR and MMR at 12 months were 
significantly higher in imatinib 800 mg arm and lower 
and comparable in imatinib 400 mg and imatinib 400 
+IFN alpha arms. MMR at 12 months have been 
reached faster with imatinib 800 mg, but this faster 
response did not translate into a better OS or 
progression-free survival (PFS).25 A Randomized 
European LekemiaNet Study addressed the issue of 
comparison of imatinib 400 mg and 800 mg daily in 
the front-line treatment of high-risk, Philadelphia-
positive CML patients. 216 high risk patients according 
to the Sokal index were randomized into a group 
treated for at least 1 year front – line with imatinib at a 
dose of 800 mg daily or 400 mg daily. At 12 months 
the rate of CCyR (the primary endpoint) was better in 
the high-dose arm than in the standard-dose arm but the 
difference was not statistically significant. Importantly, 
the number of failures and the number of patients who 
discontinued treatment for any reasons were not 
different in those two arms. The proportion of MMR at 
any time point was slightly but nonsignificantly higher 
in the high-dose arm than in the standard-dose arm. 
This large,  prospective, intention-to-treat, randomized 
study on therapy for high risk patients with CML failed 
to demonstrate a benefit of imatinib administered at a 
higher dose for the primary end point, as well as for 
any other measure of efficacy, toxicity, and 
compliance.38 In the other study of imatinib 400 mg 
versus 800 mg daily in 227 patients in late chronic 
phase who were resistant or intolerant to IFN alpha 
imatinib 800 mg daily was associated with a higher 
CCyR rate at 6 months but not at 12 months.39 The 
MMR rate at 12 months was the primary end point of 
another study of 476 patients, any risk, who were 
randomized to receive front-line imatinib at a dose of 
800 mg or 400 mg daily.40 The difference in the MMR 
rate at 12 months between 400 mg and 800 mg arm 
was not significant. These studies does not support the 
wide use of imatinib at higher dosis front-line in all 
patients suffering from CML.  
Combination of imatinib with low dose arabinosyl 
cytosine have been tested in two randomized trials, but 
none have demonstrated a superiority versus therapy 
with imatinib alone.41,22 The German CML Study IV 
was designed to compare in a randomized fashion 
standard imatinib vs. imatinib + IFN alpha  vs. imatinib 
+ low dose araC vs.  imatinib after IFN (for low- and 
intermediate-risk patients) or vs. imatinib 800 mg (for 
high-risk patients). At 3 years, the cumulative 
incidence of CHR,  MCyR, CCyR and of MMR were 
comparable for primary imatinib therapies.41 A French 
SPIRIT randomized study for untreated chronic-phase 
CML patients compared efficacy of imatinib alone at a 
dose of 400 mg daily, imatinib (400 mg daily) plus 
cytarabine (20 mg per square meter of body-surface 
area per day on days 15 through 28 of each 28-day 
cycle) or pegylated interferon (peginterferon) alfa-2a 
(90 μg weekly), or imatinib alone at a dose of 600 mg 
daily.22  At 12 months, the rates of CCyR were similar 
among the four groups.  Combination of imatinib and 
low dose arabinosyl cytosine was not superior to 
imatinib alone in any measure of efficacy. Patients 
treated with combination of imatinib and peginterferon 
alfa-2a achieved significantly better rate (30%, 38%) of 
a superior molecular response (corresponding to MR 4) 
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than patients receiving 400 mg of imatinib alone (14%, 
21%) at 1, and at 2 year respectively (P = 0.001). 
During the first year of the trial, however, 39% of the 
patients discontinued cytarabine, and 45% discontinued 
peginterferon alfa-2a, both predominantly due to a 
toxicity. A lower dose of peginterferon alfa-2a (e.g., 45 
μg per week) enhanced the tolerability while retaining 
the antileukemic efficacy. The rate of grade 3 to 4 
hematologic toxicity has been reduced from 54% to 
27%, and the proportion of patients who discontinued  
peginterferon alfa-2a before 6 months decreased from 
40% to 10%.  By 12 months, the cumulative MR4 for 
the subgroup treated with imatinib at a dose of 400 mg 
and the PegIFN90 vs imatinib of 400-mg and 
PegIFN45 were 25% and 28% respectively.42 The main 
phase of CML German Study IV compared 
monotherapy with imatinib 400 mg/d versus imatinib 
400 mg/d combined with nonpegylated IFN-alpha 
given at an initial dose of 1.5 mill.U three times per 
week and increased up to 3 mill.U three times per 
week, according to tolerability versus imatinib 800 
mg/d. At 12 months the rates of MMR which was the 
first primary end point were similar in the  
monotherapy imatinib 400 mg/d arm (44% [95% CI, 
37% to 50%]) and in the imatinib 400 mg/d combined 
with IFN-alpha  46% [95% CI, 40% to 52%] arm and 
inferior to imatinib 800 mg/d arm.25 In the Nordic trial 
newly diagnosed chronic-phase CML patients with a 
low or intermediate Sokal risk score were randomized 
either to group treated with a combination of pegylated 
IFN-alpha 2b (Peg–IFN-alpha 2b) at a dose of 50 µg 
weekly and imatinib 400 mg daily or with imatinib 400 
mg daily as a monotherapy. The MMR rate at 12 
months was significantly higher in the combination 
arm (82%) compared with the imatinib monotherapy 
arm (54%; intention-to-treat, P= .002).  In the 
combination arm, however, 61% of patients 
discontinued Peg–IFN-alpha 2b, most because of 
toxicity.43 In the MD Anderson Cancer Center 
(MDACC) trial patients were randomized to receive 
imatinib 400 mg twice daily, and combination of 
imatinib 800 mg/d with pegylated rIFN-alpha 2b 0.5 
μg/kg weekly. The MMR and the CCyR rates were 
comparable in both arms.44 None of these combination 
studies has demonstrated a superior PFS or OS for 
patients who received combined treatment.  
 
Studies on Cessation of Imatinib. Allogeneic – 
haematopoietic stem cell transplantation (Allo-HSCT) 
has been and is still considered as the sole treatment 
able to cure CML. As a result of allo-HSCT a long 
period of time free from cytogenetic or hematologic 
relapse of the disease without the need for maintenance 
therapy could be achieved.45,46 However a thorough 
monitoring of minimal residual disease with qRT-PCR 
could demonstrate a presence of the BCR-ABL gene 
transcript even a long time after transplantation, which 
does not necessarily imply relapse, because no other 
signs of disease recurrence were observed.47,48 
Apparently most of the patients were cured even 
though not all BCR-ABL positive leukemic cells were 
completely eradicated. A similar pattern is now 
observed in the course of the long-term follow-up of 
TKI-treated patients who eventually stop the treatment 
after achieving a deep and sustained molecular 
remission, and is a convincing illustration of the 
concept of „operational cure”.49 The first pilot study 
was initiated in 12 chronic phase CML patients treated 
with imatinib at a standard dose who have achieved 
and maintained a complete molecular response (CMR) 
for at least 2 years, which was assessed by qRT-PCR 
with a sensitivity ranging between a 4.5- and a 5-log 
reduction. After a median follow-up time of 18 months, 
50% of patients remained off-therapy without 
reappearance of BCR-ABL transcripts.50 Those patients 
still have an undetectable level of BCR-ABL 
transcripts after a median follow-up time of 6 years 
(range, 4-8). The same entry criteria were used for the 
multicenter study entitled the “Stop Imatinib” (STIM) 
which enrolled prospectively one hundred patients. The 
treatment with imatinib was restarted in the case of 
molecular relapse, which was arbitrarily defined as 2 
positive qRT-PCR results over a period of 1 month 
showing at least a 1 log increase in BCR-ABL 
transcripts. At 36 months the overall probability of 
molecular relapse–free, and treatment-free remission 
was 39% (95% CI, 29-48). Most patient relapsed 
within 6 months from imatinib cessation; 3 cases of 
late relapse occuring at months 19, 20, and 22, 
respectively were noted. Most patient form the pilot as 
well as from the STIM study remained responsive to 
retreatment with imatinib. The second French “Stop 
Imatinib” (STIM2) study used the same criteria as 
those for the STIM1. The molecular relapse was 
defined also in a similar way, and a loss of MMR 
detected at one point was a trigger of TKI retreatment. 
The median follow-up of 124 enrolled patients is 12 
months (range 1-25). After discontinuation of imatinib, 
a molecular relapse occurred in 48 pts (most within 6 
months form imatinib cessation; 3 relapses between 6 
and 12 month), and 76 patients (61%) were still free-of 
treatment at the last update. Forty one patients 
experienced a BCR-ABL transcript fluctuation in the 
qRT-PCR without clear molecular relapse.52 The 
TWISTER study is a prospective clinical trial which 
have used very similar as those in a STIM study entry 
and molecular relapse criteria for 40 chronic phase 
CML patients who discontinued imatinib. At 24 
months, the proportion of patients remaining in stable 
treatment-free remission was 47.1%. Most patients 
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relapsed within 4 months of stopping imatinib, 
importantly, no relapses beyond 27 months were 
observed.53 Other report demonstrates the probability 
of maintaining the CMR at 1 year of 28,6% after 
discontinuation of imatinib in 14 chronic phase CML 
patients. None of the patients however was strictly in 
CMR throughout the entire 2-year period preceding 
cessation of imatinib and half of the patients were  high 
risk according to the Sokal index.54 A nationwide 
survey conducted in Japan identified 50 patients who 
stopped imatinib for at least 6 months. Molecular 
relapse was detected in 19 out of 43 analyzed patients,  
and the CMR rate after imatinib discontinuation was 
estimated to be 47%.55 All mentioned above studies 
demonstrate the proof of concept for stopping imatinib 
in CML patients who were able to achieve a deep, 
sustained molecular response. It seems certain that an 
MMR is not enough to plan a discontinuation strategy. 
The STIM1 and STIM2 study used a 4.5 – 5-log 
reduction, and the TWISTER study used a 4.5-log 
reduction for their definition of CMR. Larger studies 
suggest that beside of the level of BCR-ABL 
transcripts after imatinib treatment, the duration of 
deep molecular response is of major importance in 
achievement of a long-term treatment-free survival. In 
the STIM1, STIM2 and TWISTER trials, a sustained 
CMR for at least 2 years was used as the 
criterion.51,52,53 In the multivariate analysis and 
logistical regression in the STIM1 study, Sokal risk and 
imatinib therapy duration were confirmed as 2 
independent prognostic factors for prediction of 
molecular relapse after imatinib discontinuation.51 It is 
obviously necessary to monitor regularly the minimal 
residual disease using qRT-PCR to allow an early 
detection of a fast molecular recurrence and restart the 
treatment as soon as possible. Most of the molecular 
recurrences occurred within the first few months of 
imatinib cessation. The presence of residual BCR-ABL 
positive cells in CML patients in CMR before and after 
imatinib discontinuation were demonstrated by Ross et 
al. who  used genomic DNA-based PCR, which allows 
to detect rearranged BCR-ABL gene at a level of 
around 1- to 2-log below the detection limit of 
conventional (mRNA) qRT-PCR. However, there was 
no link between detection of BCR-ABL by genomic 
DNA-based PCR and relapse.53 Monitoring of residual 
disease by more sensitive conventional qRT-PCR 
within STIM1 study also does not allow the prediction 
of relapse after imatinib cessation.51 Importantly some 
fluctuations in BCR-ABL levels detected by 
conventional qRT-PCR method (in 33% patients in 
STIM2 study) could be observed after discontinuation 
without confirmation of a molecular relapse. 41 
patients (33%) in STIM2 study experienced a BCR-
ABL qRT-PCR fluctuation without molecular relapse, 
confirming that BCR-ABL reappearance does not 
mean automatically clinical relapse and reinforcing the 
concept of “operational cure”.52,49 
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